✨ Onyx Summary Geron Corporation granted inducement equity awards to 11 new hires covering 522,000 shares—348,000 stock options with a $1.45 exercise price and 10-year term, and 174,000 RSUs—granted on August 15, 2025 under Nasdaq Listing Rule 5635(c)(4), with options and RSUs
✨ Onyx Summary VeriSIM Life announced that its Founder and CEO, Dr. Jo Varshney, received the 2025 International Women Entrepreneur Award in IT from Great Companies, recognizing her leadership in applying AI-driven biosimulation to transform drug development. Dr. Varshney’s work with the company’s BIOiSIM® platform—capable of predicting
✨ Onyx Summary Belite Bio reported Q2 2025 results alongside key milestones: completion of enrollment in the Phase 3 PHOENIX trial in geographic atrophy, FDA Breakthrough Therapy Designation for Tinlarebant in Stargardt disease, and the DRAGON Phase 3 trial tracking to complete in Q4 2025. As of June 30, Belite had
✨ Onyx Summary Keros Therapeutics announced a strategic realignment to focus resources on its lead program, KER-065, and discontinue internal development of cibotercept following Phase 2 data in pulmonary arterial hypertension. The company also implemented board and leadership changes, including appointing Jean-Jacques Bienaimé as Chair and promoting Lorena Lerner,
✨ Onyx Summary Adverum Biotechnologies announced that CEO Laurent Fischer, M.D., and Board Member Szilárd Kiss, M.D., will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. The discussion will be webcast live, offering insights into Adverum’s intravitreal
✨ Onyx Summary Geron Corporation appointed Harout Semerjian as President and Chief Executive Officer, effective August 7, 2025, succeeding Interim CEO Dawn Carter Bir, who will remain on the Board of Directors. Semerjian, a 30-year hematology and oncology veteran with leadership roles at Novartis, Ipsen, and GlycoMimetics, joins Geron as
✨ Onyx Summary Affinia Therapeutics has partnered with the DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium to raise awareness of BAG3 dilated cardiomyopathy (DCM) and drive early genetic testing for this life-threatening heart disease. The collaboration underscores the growing role of precision medicine in cardiovascular care and highlights Affinia’
